Cambridge Investment Research Advisors Inc. boosted its holdings in VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating) by 2.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,189,700 shares of the biopharmaceutical company's stock after acquiring an additional 43,192 shares during the quarter. Cambridge Investment Research Advisors Inc. owned 0.85% of VBI Vaccines worth $3,635,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in the business. Raymond James Financial Services Advisors Inc. increased its position in shares of VBI Vaccines by 8.8% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 267,148 shares of the biopharmaceutical company's stock valued at $443,000 after purchasing an additional 21,587 shares during the period. Raymond James & Associates increased its position in shares of VBI Vaccines by 10.2% during the 1st quarter. Raymond James & Associates now owns 676,516 shares of the biopharmaceutical company's stock valued at $1,123,000 after purchasing an additional 62,638 shares during the period. JPMorgan Chase & Co. increased its position in shares of VBI Vaccines by 58.3% during the 1st quarter. JPMorgan Chase & Co. now owns 117,846 shares of the biopharmaceutical company's stock valued at $196,000 after purchasing an additional 43,415 shares during the period. Swiss National Bank increased its position in shares of VBI Vaccines by 8.3% during the 1st quarter. Swiss National Bank now owns 425,800 shares of the biopharmaceutical company's stock valued at $707,000 after purchasing an additional 32,700 shares during the period. Finally, Wealthsource Partners LLC bought a new stake in shares of VBI Vaccines during the 1st quarter worth $238,000. 39.96% of the stock is currently owned by institutional investors and hedge funds.
Get VBI Vaccines alerts:Analyst Upgrades and Downgrades
Separately, Raymond James reduced their price objective on VBI Vaccines from $6.00 to $5.00 and set a "strong-buy" rating for the company in a research note on Tuesday, August 9th.
VBI Vaccines Stock Performance
VBIV opened at $0.92 on Friday. The firm has a market cap of $236.36 million, a PE ratio of -2.35 and a beta of 1.92. The company has a quick ratio of 2.19, a current ratio of 2.29 and a debt-to-equity ratio of 0.20. The business has a fifty day simple moving average of $0.93 and a 200-day simple moving average of $1.16. VBI Vaccines Inc. has a fifty-two week low of $0.64 and a fifty-two week high of $3.76.
VBI Vaccines (NASDAQ:VBIV – Get Rating) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.11). The company had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.70 million. VBI Vaccines had a negative return on equity of 75.37% and a negative net margin of 15,391.36%. As a group, equities analysts predict that VBI Vaccines Inc. will post -0.37 EPS for the current fiscal year.
VBI Vaccines Company Profile
(Get Rating)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
Featured Articles
- Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
- Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
- DocuSign Has Important Issues to Address When it Reports Earnings
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.